tsquared
05-06-2006, 05:09 AM
Research study of an investigational medication for the treatment of Depression.
Study Description:
This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, active-controlled study of the efficacy and safety of sustained-release Quetiapine Fumarate (SEROQUEL) compared with placebo in the treatment of patients with depressive Disorder.
Length of study: Approximately 9-weeks.
Number of office visits: 8
At no cost, qualified participants may receive study medication and study related services. In addition, there is compensation of up to $500.00 for completion of the study.
Study inclusion/exclusion criteria:
You may qualify for this study if you:
• Are 18 to 65 years old
• Are without serious health problems
• Are not addicted to drugs or alcohol
• Do not have certain conditions such as Bipolar disorder
Contact us at:
California Neuroscience Research Medical Group, Inc.
4835 Van Nuys Blvd., Suite 104
Sherman Oaks, CA 91403
(818) 990-2671
keith@cnrmg.com
Study Description:
This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, active-controlled study of the efficacy and safety of sustained-release Quetiapine Fumarate (SEROQUEL) compared with placebo in the treatment of patients with depressive Disorder.
Length of study: Approximately 9-weeks.
Number of office visits: 8
At no cost, qualified participants may receive study medication and study related services. In addition, there is compensation of up to $500.00 for completion of the study.
Study inclusion/exclusion criteria:
You may qualify for this study if you:
• Are 18 to 65 years old
• Are without serious health problems
• Are not addicted to drugs or alcohol
• Do not have certain conditions such as Bipolar disorder
Contact us at:
California Neuroscience Research Medical Group, Inc.
4835 Van Nuys Blvd., Suite 104
Sherman Oaks, CA 91403
(818) 990-2671
keith@cnrmg.com